Abstract: The data provided herewith show that, biomarkers found within the cells of a tumor or cancer may also be present at adequate levels within the patient's urine to enable detection. Method of diagnosis, patient selection and treatment are provided, along with kits and devices.

Abstract: Previously, we have shown that a cancer associated-PRL-3 intracellular phosphatase is a potential therapeutic target for PRL-3 antibody therapy. PRL-3 has recently emerged as a potentially useful biomarker for cancer prognosis, particularly the prediction of cancer metastasis (Matsukawa et al, 2010, Ren et al, 12 2009). Here we demonstrate that PRL-3 can act as an independent prognostic marker for cancers.

Abstract: We provide VHZ for use in a method of treatment, prophylaxis or alleviation of a cancer in an individual selected from the group consisting of: colon cancer, lung cancer, squamous cell carcinoma including lip, larynx, vulva, cervix and penis cancer, pancreatic cancer, brain cancer, oesophageal cancer, stomach cancer, bladder cancer, kidney cancer, skin cancer, ovary cancer, prostate cancer and testicular cancer. We provide an anti-VHZ agent for the treatment, prophylaxis or alleviation of such a cancer. The anti-VHZ agent may comprise SEQ ID NO:4 or SEQ ID NO: 5, or both.

Abstract: We provide an antibody capable of binding to an intracellular PRL-I or PRL-3 polypeptide, in which the antibody is capable of binding to an epitope bound by antibody 269, antibody 223 or antibody 318. Such anti-PRL antibodies may be capable of binding to intracellular PRL-I or PRL-3. They may be suitable for use as therapies against cancer or metastasis thereof, or in clinical diagnosis to identify PRL-3 or PRL-1 positive patients.

Abstract: A bulky consolidated nanostructured manganese aluminum alloy includes at least about 80% of a magnetic ? phase and having a macroscopic composition of MnXAlYDoZ, where Do is a dopant, X ranges from 52-58 atomic percent, Y ranges from 42-48 atomic percent, and Z ranges from 0 to 3 atomic percent. A method for producing a bulky nanocrystalline solid of formula MnxAlyDoz is provided. The method includes melting a mixture of metals to form a substantially homogenous solution, casting the solution to form ingots, measuring compositions of the ingots; crushing the ingots to form crushed powders, and milling the crushed powders to form nanocrystalline powders. The method further includes verifying the presence of ? phase and determining the amount of the ? phase, and simultaneously consolidating the nanocrystalline powders into a bulky nanocrystalline solid and undergoing phase transformation from ? phase to at least 80% ? phase.

Abstract: We provide an antibody capable of binding to an intracellular PRL-I or PRL-3 polypeptide, in which the antibody is capable of binding to an epitope bound by antibody 269, antibody 223 or antibody 318. Such anti-PRL antibodies may be capable of binding to intracellular PRL-I or PRL-3. They may be suitable for use as therapies against cancer or metastasis thereof, or in clinical diagnosis to identify PRL-3 or PRL-I positive patients.

Abstract: We provide a polypeptide vaccine for treatment and prevention of cancer, particularly prevention of metastasis of cancer. Also provided are methods of treating or preventing cancer, and pharmaceutical compositions comprising the polypeptide vaccine.

Abstract: The present invention relates to novel quinoxaline compounds of Formula I: as Fatty Acid Binding Protein (“FABP”) inhibitors, pharmaceutical compositions comprising the quinoxaline compounds and the use of the quinoxaline compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose.

Abstract: We provide an antibody capable of binding to an intracellular PRL-I or PRL-3 polypeptide, in which the antibody is capable of binding to an epitope bound by antibody 269, antibody 223 or antibody 318. Such anti-PRL antibodies may be capable of binding to intracellular PRL-I or PRL-3. They may be suitable for use as therapies against cancer or metastasis thereof, or in clinical diagnosis to identify PRL-3 or PRL-I positive patients.

Abstract: We provide VHZ for use in a method of treatment, prophylaxis or alleviation of a cancer, such as breast cancer, in an individual. We provide an anti-VHZ agent for the treatment, prophylaxis or alleviation of cancer. We further provide a kit for detecting breast cancer in an individual or susceptibility of the individual to breast cancer comprising means for detection of VHZ expression in the individual or a sample taken from him or her as well as a method of detecting a cancer cell, the method comprising detecting modulation of expression, amount or activity of VHZ in the cell.

Abstract: We provide VHZ for use in a method of treatment, prophylaxis or alleviation of a cancer, such as breast cancer, in an individual. We provide an anti-VHZ agent for the treatment, prophylaxis or alleviation of cancer. We further provide a kit for detecting breast cancer in an individual or susceptibility of the individual to breast cancer comprising means for detection of VHZ expression in the individual or a sample taken from him or her as well as a method of detecting a cancer cell, the method comprising detecting modulation of expression, amount or activity of VHZ in the cell.

Abstract: We provide an antibody capable of binding to an intracellular PRL-1 or PRL-3 polypeptide, in which the antibody is capable of binding to an epitope bound by antibody 269, antibody 223 or antibody 318. Such anti-PRL antibodies may be capable of binding to intracellular PRL-1 or PRL-3. They may be suitable for use as therapies against cancer or metastasis thereof, or in clinical diagnosis to identify PRL-3 or PRL-1 positive patients.

Abstract: An electronic device includes a housing defining an opening, a button body and a sealing member. The button body includes a cap member, a key rod, a resisting rod, and a protruding member. The protruding member protrudes from a lateral surface of the resisting rod. The protruding member includes a resisting surface. The sealing member is integrally formed with the housing at the opening. The sealing member includes a main body arranged in the opening and a positioning member protruding from the main body. The positioning member defines a receiving hole including an opening end. The key rod is inserted into the receiving hole through the opening end. The sealing member defines a first through hole. The resisting rod extends through the first through hole, the sealing member is urged to elastically deform by the resisting surface, and the first through hole is tightly engaged with the resisting rod.

Abstract: We provide for the use of an intracellular antibody therapy for targeting intracellular oncoproteins or proteins to prevent cancer metastasis. We also provide for the use of an intracellular vaccine therapy comprising an oncoprotein protein for vaccination to stimulate a host to produce its own antibodies to prevent tumor formation. The antibody may comprise a chimeric antibody.

Abstract: The present invention relates to novel heterocyclic compounds as Fatty Acid Binding Protein (“FABP”) inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose.

Abstract: A bulky consolidated nanostructured manganese aluminum alloy includes at least about 80% of a magnetic ? phase and having a macroscopic composition of MnXAlYDoZ, where Do is a dopant, X ranges from 52-58 atomic %, Y ranges from 42-48 atomic %, and Z ranges from 0 to 3 atomic %. A method for producing a bulky nanocrystalline solid is provided. The method includes melting a mixture of metals to form a substantially homogenous solution. The method also includes casting the solution to form ingots, measuring compositions of the ingots; crushing the ingots to form crushed powders, and milling the crushed powders to form nanocrystalline powders. The method further includes verifying the presence of ? phase and determining the amount of the ? phase, and simultaneously consolidating the nanocrystalline powders into a bulky nanocrystalline solid and undergoing phase transformation from ? phase to at least 80% ? phase, ? and ?2 phases.

Abstract: We provide an antibody capable of FIG. 13A, FIG. 13B binding to an intracellular PRL-1 or PRL-3 polypeptide, in which the antibody is capable of binding to an epitope bound by antibody 269, antibody 223 or antibody 318. Such anti-PRL antibodies may be capable of binding to intracellular PRL-1 or PRL-3. They may be suitable for use as therapies against cancer or metastasis thereof, or in clinical diagnosis to identify PRL-3 or PRL-1 positive patients.

Abstract: We provide VHZ for use in a method of treatment, prophylaxis or alleviation of a cancer in an individual selected from the group consisting of: colon cancer, lung cancer, squamous cell carcinoma including lip, larynx, vulva, cervix and penis cancer, pancreatic cancer, brain cancer, oesophageal cancer, stomach cancer, bladder cancer, kidney cancer, skin cancer, ovary cancer, prostate cancer and testicular cancer. We provide an anti-VHZ agent for the treatment, prophylaxis or alleviation of such a cancer. The anti-VHZ agent may comprise SEQ ID NO:4 or SEQ ID NO: 5, or both.

Abstract: The present invention is a nanoparticle composition composed of an iron core with an iron oxide shell which is optionally coated with a micro-emulsion. The disclosed nanoparticle compositions are disclosed for use in hyperthermia treatment and imaging of cancer.

Abstract: Nanostructured Mn—Al and Mn—Al—C permanent magnets are disclosed. The magnets have high coercivities (˜4.8 kOe and 5.2 kOe, respectively) and high saturation magnetization values. The magnets are prepared from cost effective and readily available elements using a novel mechanical milling and annealing method.